Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

PD-L1 ELISA Kit

Dieses Colorimetric ELISA-Kit wurde entwickelt für die quantitative Messung von Human PD-L1.
Produktnummer ABIN5026969

Kurzübersicht für PD-L1 ELISA Kit (ABIN5026969)

Target

Alle PD-L1 ELISA Kits anzeigen
PD-L1 (CD274 (PD-L1))

Reaktivität

  • 12
  • 6
  • 4
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
Human

Nachweismethode

Colorimetric

Methodentyp

Sandwich ELISA

Detektionsbereich

0.156-10 ng/mL

Applikation

ELISA

Proben

Plasma, Serum
  • Untere Nachweisgrenze

    0.156 ng/mL

    Verwendungszweck

    This immunoassay kit allows for the in vitro quantitative determination of Human PDL1 concentrations in serum, plasma and other biological fluids. This kit is for Research use only. Not for use in diagnostic/therapeutics procedures.

    Analytische Methode

    Quantitative

    Sensitivität

    < 94 pg/mL

    Bestandteile

    plate, standard, diluent, antibodies

    Benötigtes Material

    pipettes, tubes, reader, incubator
  • Probenmenge

    100 μL

    Testdauer

    3 - 4 h

    Plattentyp

    Pre-coated

    Protokoll

    This assay employs an antibody specific for Anti-human PD-L1 coated on a 96-well plate. Standards and samples are pipetted into the wells and PD-L1present in a sample is bound to the wells by the immobilized antibody. The wells are washed and biotinylated anti-human PD-L1 antibody is added. After washing away unbound biotinylated antibody, HRP-conjugated streptavidin is pipetted to the wells. The wells are again washed, a TMB substrate solution is added to the wells and color develops in proportion to the amount of PD-L1 bound. The Stop Solution changes the color from blue to yellow, and the intensity of the color is measured at 450 nm.

    Beschränkungen

    Nur für Forschungszwecke einsetzbar
  • Vorsichtsmaßnahmen

    protect your eyes

    Lagerung

    4 °C
  • Target Alle PD-L1 ELISA Kits anzeigen

    PD-L1 (CD274 (PD-L1))

    Andere Bezeichnung

    PD-L1

    Pathways

    Cancer Immune Checkpoints
Sie sind hier:
Chat with us!